Why consider treatment in China for Macular Degeneration?

China offers advanced, cost-effective treatment for wet AMD using anti-VEGF intravitreal injections such as aflibercept, ranibizumab, and the locally developed biosimilar conbercept. Chinese ophthalmology centers are equipped with state-of-the-art diagnostic and injection technology, and many specialists have trained internationally. The lower cost of medications and procedures, combined with high clinical volumes, ensures competitive pricing without compromising quality.